Drug Combination Details
| General Information of the Combination (ID: C80064) | |||||
|---|---|---|---|---|---|
| Name | Curcumin NP Info | + | Imatinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute lymphoblastic leukemia
[ICD-11: 2B33]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ABL | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCR | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SUP-B15 | CVCL_0103 | B acute lymphoblastic leukemia | Homo sapiens | ||
| THP-1 | CVCL_0006 | Childhood acute monocytic leukemia | Homo sapiens | |||
| ARAC-8C | CVCL_GZ09 | T acute lymphoblastic leukemia | Homo sapiens | |||
| In-vivo Model | Female BALB/c null mice were injected with 107 SUP-B15 cells via tail vein. | |||||
| Experimental
Result(s) |
Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph+ acute lymphoblastic leukemia. | |||||
